Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket ... its gene-editing treatment for sickle cell disease and beta-thalassemia. Analysts responded positively to the results.

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

Investors were feeling zen on Wednesday, with no major news about Donald Trump's tariffs to worry about ahead of the monthly ...

One bad year continues to haunt university endowments’ performance. U.S. school funds had a strong fiscal year, rising an average 11.2% in the 12 months through June 30. “Fiscal 2022 is going to stick ...